8 assets in Diffuse Midline Glioma, H3 K27-Altered

Therapeutic assets addressing Diffuse Midline Glioma, H3 K27-Altered, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cetuximab Diffuse Midline Glioma, H3 K27-Altered	University of Miami	P1/2	CCC (48)
Cbl-0137 Free Base Diffuse Midline Glioma, H3 K27-Altered	Children's Oncology Group	P1/2	CC (44)
Atezolizumab Diffuse Midline Glioma, H3 K27-Altered	German Cancer Research Center	P1	CC (43)
h3k27m peptide vaccine Diffuse Midline Glioma, H3 K27-Altered	German Cancer Research Center	P1	CC (43)
Imiquimod Diffuse Midline Glioma, H3 K27-Altered	German Cancer Research Center	P1	CC (43)
Vipivotide Tetraxetan Diffuse Midline Glioma, H3 K27-Altered	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Lorlatinib Diffuse Midline Glioma, H3 K27-Altered	Nationwide Children's Hospital	Early P1	C (39)
azd1390 Diffuse Midline Glioma, H3 K27-Altered	Children's Oncology Group	P1	NR ()